fb_script

Children with type 1 diabetes at risk of acute kidney injury following DKA

A new study has found that children with type 1 diabetes (T1D) who are hospitalised for Diabetic Ketoacidosis (DKA) are more likely to develop acute kidney injury (AKI), a sudden episode of renal failure or damage. DKA is a severe complication that occurs with prolonged hyperglycaemia. It may occur at the initial presentation of newly diagnosed T1D or in someone with pre-existing T1D in times of illness or insulin omission.
Read More

Australian diabetes expert receives Australia Day honour

JDRF is proud to congratulate Professor Mark Cooper, Head of Diabetes in the Faculty of Medicine, Nursing and Health Sciences at Monash University, who was awarded an AO (Officer in the General Division of the Order of Australia) on Australia Day this month.

imageedit_1_3004952851

This award is the most prestigious means of recognising outstanding members of the community at a national level.

Read More

Australian diabetes expert recognised with prestigious international award

JDRF-funded researcher Professor Mark Cooper, Chief Scientific Officer and Head of the Diabetes Division at Baker IDI Heart and Diabetes Research Institute, has become the first Australian to receive the prestigious Claude Bernard award from the European Association for the Study of Diabetes this month.  Read More

Sanofi and Lexicon Pharmaceuticals partner on new non-insulin therapy for type 1 diabetes

JDRF partner Sanofi and Lexicon Pharmaceuticals have announced a new collaboration to develop and commercialise a new oral drug for the treatment of type 1 diabetes.

Nadav Kidron, CEO of Oramed Pharmaceuticals, poses for a photo in Jerusalem

The drug is called sotagliflozin and is used in conjunction with insulin to help improve blood glucose levels by blocking glucose absorption in the kidneys and the gut.  Read More